Basit öğe kaydını göster

dc.contributor.authorJakab, Ivett
dc.contributor.authorNemeth, Bertalan
dc.contributor.authorElezbawy, Baher
dc.contributor.authorKaradayı, Melis Almula
dc.contributor.authorTozan, Hakan
dc.contributor.authorAydın, Sabahattin
dc.contributor.authorShen, Jie
dc.contributor.authorKalo, Zoltan
dc.date.accessioned2020-09-28T08:57:26Z
dc.date.available2020-09-28T08:57:26Z
dc.date.issued2020en_US
dc.identifier.citationJakab, I., Nemeth, B., Elezbawy, B., Karadayı, M. A., Tozan, H., Aydın, S. ... Kalo, Z. (2020). Potential criteria for frameworks to support the evaluation of innovative medicines in upper middle-income countries-A systematic literature review on value frameworks and multi-criteria decision analyses. Frontiers in Pharmacology, 11. https://dx.doi.org/10.3389/fphar.2020.01203en_US
dc.identifier.issn1663-9812
dc.identifier.urihttps://dx.doi.org/10.3389/fphar.2020.01203
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5874
dc.description.abstractBackground Multicriteria Decision Analysis (MCDA), a formal decision support framework, has been growing in popularity recently in the field of health care. MCDA can support pricing and reimbursement decisions on the macro level, which is of great importance especially in countries with more limited resources. Objectives The aim of this systematic review was to facilitate the development of future MCDA frameworks, by proposing a set of criteria focusing on the purchasing decisions of single-source innovative pharmaceuticals in upper middle-income countries. Methods A systematic literature review was conducted on the decision criteria included in value frameworks (VFs) or MCDA tools. Scopus, Medline, databases of universities, websites of Health Technology Assessment Agencies, and other relevant organizations were included in the search. Double title-abstract screening and double full-text review were conducted, and all extracted data were double-checked. A team of researchers performed the merging and selection process of the extracted criteria. Results A total of 1,878 articles entered the title and abstract screening. From these, 341 were eligible to the full-text review, and 36 were included in the final data extraction phase. From these articles 394 criteria were extracted in total. After deduplication and clustering, 26 different criteria were identified. After the merging and selection process, a set of 16 general criteria was proposed. Conclusion Based on the results of the systematic literature review, a pool of 16 criteria was selected. This can serve as a starting point for constructing MCDA frameworks in upper middle-income countries after careful adaptation to the local context.en_US
dc.description.sponsorshipNovartis International AGen_US
dc.language.isoengen_US
dc.publisherFrontiers Media SAen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectHealth Technology Assessmenten_US
dc.subjectPharmaceuticalen_US
dc.subjectReimbursementen_US
dc.subjectDeveloping Countryen_US
dc.subjectMultiple Criteriaen_US
dc.titlePotential criteria for frameworks to support the evaluation of innovative medicines in upper middle-income countries-A systematic literature review on value frameworks and multi-criteria decision analysesen_US
dc.typereviewen_US
dc.relation.ispartofFrontiers in Pharmacologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Endüstri Mühendisliği Bölümüen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.authorid0000-0002-6959-9168en_US
dc.authorid0000-0002-0479-6937en_US
dc.authorid0000-0001-6374-817Xen_US
dc.identifier.volume11en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.3389/fphar.2020.01203en_US
dc.identifier.wosqualityQ1en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess